Jaya Sangodkar
Overview
Explore the profile of Jaya Sangodkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rasool R, OConnor C, Das C, Alhusayan M, Verma B, Islam S, et al.
Nat Commun
. 2023 Aug;
14(1):5253.
PMID: 37644036
Loss of the tumor suppressive activity of the protein phosphatase 2A (PP2A) is associated with cancer, but the underlying molecular mechanisms are unclear. PP2A holoenzyme comprises a heterodimeric core, a...
2.
OConnor C, Taylor S, Miller K, Hurst L, Haanen T, Suhan T, et al.
Cancer Res
. 2021 Dec;
82(4):721-733.
PMID: 34921012
Significance: A drug repurposing screen identifies synthetic lethal interactions in PP2A-deficient uterine serous carcinoma, providing potential therapeutic avenues for treating this deadly endometrial cancer.
3.
Scarpa M, Singh P, Bailey C, Lee J, Kapoor S, Lapidus R, et al.
Mol Cancer Ther
. 2021 Feb;
20(4):676-690.
PMID: 33568357
-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is...
4.
Noto F, Sangodkar J, Adedeji B, Moody S, McClain C, Tong M, et al.
PLoS One
. 2020 Oct;
15(10):e0240169.
PMID: 33027304
We have created the immunodeficient SRG rat, a Sprague-Dawley Rag2/Il2rg double knockout that lacks mature B cells, T cells, and circulating NK cells. This model has been tested and validated...
5.
Coles G, Cristea S, Webber J, Levin R, Moss S, He A, et al.
Cancer Cell
. 2020 Jun;
38(1):129-143.e7.
PMID: 32531271
Using unbiased kinase profiling, we identified protein kinase A (PKA) as an active kinase in small cell lung cancer (SCLC). Inhibition of PKA activity genetically, or pharmacologically by activation of...
6.
Farrington C, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen B, et al.
J Biol Chem
. 2019 Dec;
295(3):757-770.
PMID: 31822503
The tumor suppressor protein phosphatase 2A (PP2A) is a serine/threonine phosphatase whose activity is inhibited in most human cancers. One of the best-characterized PP2A substrates is MYC proto-oncogene basic helix-loop-helix...
7.
OConnor C, Leonard D, Wiredja D, Avelar R, Wang Z, Schlatzer D, et al.
Oncogene
. 2019 Sep;
39(3):703-717.
PMID: 31541192
The serine/threonine Protein Phosphatase 2A (PP2A) functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways. The canonical PP2A holoenzyme comprises a scaffolding subunit (PP2A Aα/β), which serves...
8.
Taylor S, OConnor C, Wang Z, Shen G, Song H, Leonard D, et al.
Cancer Res
. 2019 May;
79(16):4242-4257.
PMID: 31142515
Somatic mutation of the protein phosphatase 2A (PP2A) Aα-subunit gene is highly prevalent in high-grade endometrial carcinoma. The structural, molecular, and biological basis by which the most recurrent endometrial carcinoma-specific...
9.
Tohme R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, et al.
JCI Insight
. 2019 Mar;
4(4).
PMID: 30830869
Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired resistance to these agents via mechanisms...
10.
Mazhar S, Taylor S, Sangodkar J, Narla G
Biochim Biophys Acta Mol Cell Res
. 2018 Nov;
1866(1):51-63.
PMID: 30401535
The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant...